Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ANLN
REST API REST API
Homo sapiens
ANLN is differentially expressed in 194 experiments: 102 organism parts: spinal cord, bone marrow, ... (100 more);, 87 disease states: normal, breast carcinoma, ... (85 more);, 74 cell types 276 cell lines 16 compound treatments and 54 other conditions.
Synonyms Scraps, ANILLIN, scra
Orthologs ANLN (Danio rerio)   ENSCING00000002822 (Ciona intestinalis)   Anln (Mus musculus)   ANLN (Bos taurus)   ANLN (Gallus gallus)   D4A0V6_RAT (Rattus norvegicus)   anln (Xenopus laevis)   ANLN (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cytoplasm, actomyosin contractile ring, cell cortex, cell cycle, actin cytoskeleton, nucleus, cytokinesis, mitosis, regulation of exit from mitosis, actin binding, septin ring assembly
InterPro Term Pleckstrin_homology
UniProt Accession C9J0G4, Q9NQW6, C9JJT6
Search EB-eye ENSG00000011426
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-GEOD-6919, E-TABM-130, ... (13 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-GEOD-14464, E-GEOD-19639, E-GEOD-29119, ... (24 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
HCC1954
2
E-GEOD-29119, E-MTAB-37
LNCaP
2
E-GEOD-14464, E-GEOD-14990
AN3CA
1
E-MTAB-37
SKOV-3
1
E-GEOD-20272
A375
1
E-MTAB-37
270 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-20677, E-GEOD-4219, E-MEXP-1216, ... (29 experiments)

Factor Value U/D Experiments
CD4+ T cell
2
E-GEOD-16190, E-AFMX-5
iPSC derived from hASC using lentiviral reprogramming vector
1
E-GEOD-20033
macrophage
1
E-GEOD-5099
mesendoderm/endoderm progenitor cell
1
E-MEXP-930
CD34 positive
1
1
E-GEOD-12662
breast cancer
1
E-GEOD-29119
68 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-882, E-MEXP-1121, ... (43 experiments)

Factor Value U/D Experiments
cervical carcinoma
2
E-MTAB-37, E-GEOD-5823
glioblastoma
2
E-MTAB-37, E-GEOD-4290
breast carcinoma
1
2
E-GEOD-5823, E-MEXP-882, E-TABM-276
control
1
2
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121
retinoblastoma
1
E-MTAB-37
follicular hyperplasia
1
E-GEOD-7788
81 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-GEOD-5741, E-TABM-782, E-TABM-127, ... (10 experiments)

Factor Value U/D Experiments
none
1
3
E-TABM-782, E-MEXP-1958, E-GEOD-7400, E-TABM-127
granulocyte-colony stimulating factor
1
E-GEOD-7400
Cxcl12
1
1
E-GEOD-7307
TGF
1
E-GEOD-15205
unknown
1
E-GEOD-7307
AMP
1
1
E-MEXP-2285
10 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-20499, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-26, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-TABM-868, E-TABM-601, E-MEXP-1838, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-GEOD-13073, E-GEOD-12773, E-GEOD-20540, E-GEOD-20504, E-GEOD-19018, ... (10 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-1290, E-GEOD-19330, ... (20 experiments)

Infection
studied in E-MEXP-561

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-GEOD-9171

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1657, E-GEOD-1460

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, E-GEOD-15799, ... (6 experiments)

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Processing time: 0.393 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM